Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.

Spearman P, Tomaras GD, Montefiori DC, Huang Y, Elizaga ML, Ferrari G, Alam SM, Isaacs A, Ahmed H, Hural J, McElrath MJ, Ouedraogo L, Pensiero M, Butler C, Kalams SA, Overton ET, Barnett SW; HVTN 088 Protocol Team and the NIH/NIAID HIV Vaccine Trials Network.

J Infect Dis. 2019 May 5;219(11):1755-1765. doi: 10.1093/infdis/jiz008.

PMID:
30615119
2.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.

Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.

3.

Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015.

Weniger BG, Anglin IE, Tong T, Pensiero M, Pullen JK; Nucleic Acid Delivery Devices for HIV Vaccines Workshop Group.

Vaccine. 2018 Jan 25;36(4):427-437. doi: 10.1016/j.vaccine.2017.10.071. Epub 2017 Nov 22.

PMID:
29174315
4.

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.

Churchyard G, Mlisana K, Karuna S, Williamson AL, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N, Yu C, Mkhize NN, Hermanus T, Allen M, Pensiero M, Barnett SW, Gray G, Bekker LG, Montefiori DC, Kublin J, Corey L.

PLoS One. 2016 Sep 1;11(9):e0161753. doi: 10.1371/journal.pone.0161753. eCollection 2016.

5.

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.

Gray GE, Mayer KH, Elizaga ML, Bekker LG, Allen M, Morris L, Montefiori D, De Rosa SC, Sato A, Gu N, Tomaras GD, Tucker T, Barnett SW, Mkhize NN, Shen X, Downing K, Williamson C, Pensiero M, Corey L, Williamson AL.

Clin Vaccine Immunol. 2016 Jun 6;23(6):496-506. doi: 10.1128/CVI.00717-15. Print 2016 Jun.

6.

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).

Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD, Sheets R, Pensiero M, Tremblay MA, Higgins TJ, Latham T, Egan MA, Clarke DK, Eldridge JH; HVTN 090 Study Group and the National Institutes of Allergy and Infectious Diseases HIV Vaccine Trials Network, Mulligan M, Rouphael N, Estep S, Rybczyk K, Dunbar D, Buchbinder S, Wagner T, Isbell R, Chinnell V, Bae J, Escamilla G, Tseng J, Fair R, Ramirez S, Broder G, Briesemeister L, Ferrara A.

Open Forum Infect Dis. 2015 Jun 5;2(3):ofv082. doi: 10.1093/ofid/ofv082. eCollection 2015 Sep.

7.

Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Wieczorek L, Krebs SJ, Kalyanaraman V, Whitney S, Tovanabutra S, Moscoso CG, Sanders-Buell E, Williams C, Slike B, Molnar S, Dussupt V, Alam SM, Chenine AL, Tong T, Hill EL, Liao HX, Hoelscher M, Maboko L, Zolla-Pazner S, Haynes BF, Pensiero M, McCutchan F, Malek-Salehi S, Cheng RH, Robb ML, VanCott T, Michael NL, Marovich MA, Alving CR, Matyas GR, Rao M, Polonis VR.

J Virol. 2015 Aug;89(15):7478-93. doi: 10.1128/JVI.00412-15. Epub 2015 May 13.

8.

Now that you want to take your HIV/AIDS vaccine/biological product research concept into the clinic: what are the "cGMP"?

Sheets RL, Rangavajhula V, Pullen JK, Butler C, Mehra V, Shapiro S, Pensiero M.

Vaccine. 2015 Apr 8;33(15):1757-66. doi: 10.1016/j.vaccine.2015.02.003. Epub 2015 Feb 16. Review.

9.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, Robinson HL; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network.

J Infect Dis. 2014 Jul 1;210(1):99-110. doi: 10.1093/infdis/jiu003. Epub 2014 Jan 7.

10.

Recent advances in humanized mice: accelerating the development of an HIV vaccine.

Tager AM, Pensiero M, Allen TM.

J Infect Dis. 2013 Nov;208 Suppl 2:S121-4. doi: 10.1093/infdis/jit451.

11.

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, Fuchs J, Koblin B, Kim DH, Joseph P, Keefer MC, Baden LR, Eldridge J, Boyer J, Sherwat A, Cardinali M, Allen M, Pensiero M, Butler C, Khan AS, Yan J, Sardesai NY, Kublin JG, Weiner DB; NIAID HIV Vaccine Trials Network.

J Infect Dis. 2013 Sep 1;208(5):818-29. doi: 10.1093/infdis/jit236. Epub 2013 Jul 8.

12.

Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.

Wecker M, Gilbert P, Russell N, Hural J, Allen M, Pensiero M, Chulay J, Chiu YL, Abdool Karim SS, Burke DS; HVTN 040/059 Protocol Team; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2012 Oct;19(10):1651-60. Epub 2012 Aug 22.

13.

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2011 Feb 24;29(10):1948-58. doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7.

14.

Current advances and challenges in HIV-1 vaccines.

Rodriguez-Chavez IR, Allen M, Hill EL, Sheets RL, Pensiero M, Bradac JA, D'Souza MP.

Curr HIV/AIDS Rep. 2006 Feb;3(1):39-47. Review.

PMID:
16522258
15.

Breeding of retroviruses by DNA shuffling for improved stability and processing yields.

Powell SK, Kaloss MA, Pinkstaff A, McKee R, Burimski I, Pensiero M, Otto E, Stemmer WP, Soong NW.

Nat Biotechnol. 2000 Dec;18(12):1279-82.

PMID:
11101807
16.

Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC).

Liu JM, Kim S, Read EJ, Futaki M, Dokal I, Carter CS, Leitman SF, Pensiero M, Young NS, Walsh CE.

Hum Gene Ther. 1999 Sep 20;10(14):2337-46.

PMID:
10515453
17.

Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation.

Dunbar CE, Kohn DB, Schiffmann R, Barton NW, Nolta JA, Esplin JA, Pensiero M, Long Z, Lockey C, Emmons RV, Csik S, Leitman S, Krebs CB, Carter C, Brady RO, Karlsson S.

Hum Gene Ther. 1998 Nov 20;9(17):2629-40.

PMID:
9853529
18.

Purified, soluble recombinant mouse hepatitis virus receptor, Bgp1(b), and Bgp2 murine coronavirus receptors differ in mouse hepatitis virus binding and neutralizing activities.

Zelus BD, Wessner DR, Williams RK, Pensiero MN, Phibbs FT, deSouza M, Dveksler GS, Holmes KV.

J Virol. 1998 Sep;72(9):7237-44.

19.

Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum.

Pensiero MN, Wysocki CA, Nader K, Kikuchi GE.

Hum Gene Ther. 1996 Jun 10;7(9):1095-101.

PMID:
8773511
21.

Mouse hepatitis virus strain A59 and blocking antireceptor monoclonal antibody bind to the N-terminal domain of cellular receptor.

Dveksler GS, Pensiero MN, Dieffenbach CW, Cardellichio CB, Basile AA, Elia PE, Holmes KV.

Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1716-20.

22.

Several members of the mouse carcinoembryonic antigen-related glycoprotein family are functional receptors for the coronavirus mouse hepatitis virus-A59.

Dveksler GS, Dieffenbach CW, Cardellichio CB, McCuaig K, Pensiero MN, Jiang GS, Beauchemin N, Holmes KV.

J Virol. 1993 Jan;67(1):1-8.

23.

Hantaan virus infection of human endothelial cells.

Pensiero MN, Sharefkin JB, Dieffenbach CW, Hay J.

J Virol. 1992 Oct;66(10):5929-36.

24.
25.
26.

Cloning of the mouse hepatitis virus (MHV) receptor: expression in human and hamster cell lines confers susceptibility to MHV.

Dveksler GS, Pensiero MN, Cardellichio CB, Williams RK, Jiang GS, Holmes KV, Dieffenbach CW.

J Virol. 1991 Dec;65(12):6881-91.

27.
28.

The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka).

Kinchington PR, Ling P, Pensiero M, Moss B, Ruyechan WT, Hay J.

J Virol. 1990 Sep;64(9):4540-8.

29.

A possible role for glycoprotein gpV in the pathogenesis of varicella-zoster virus.

Kinchington PR, Ling P, Pensiero M, Gershon A, Hay J, Ruyechan WT.

Adv Exp Med Biol. 1990;278:83-91. No abstract available.

PMID:
1963048
30.

Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant.

Pensiero MN, Jennings GB, Schmaljohn CS, Hay J.

J Virol. 1988 Mar;62(3):696-702.

31.

Dress and self-esteem.

Pensiero M, Adams M.

J Gerontol Nurs. 1987 Oct;13(10):11-7. No abstract available.

PMID:
3668176
32.

Supplemental Content

Loading ...
Support Center